Literature DB >> 6151067

Convulsions due to high-dose busulphan.

R E Marcus, J M Goldman.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1984        PMID： 6151067     DOI： 10.1016/s0140-6736(84)91649-0

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  11 in total

1.  The effect of hepatic enzyme inducers on busulfan neurotoxicity and myelotoxicity.

Authors:  W E Fitzsimmons; R Ghalie; H Kaizer
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

Review 2.  Clinical features, pathogenesis and management of drug-induced seizures.

Authors:  G Zaccara; G C Muscas; A Messori
Journal:  Drug Saf       Date:  1990 Mar-Apr       Impact factor: 5.606

Review 3.  The role of busulfan in bone marrow transplantation.

Authors:  M Hassan
Journal:  Med Oncol       Date:  1999-09       Impact factor: 3.064

4.  Association of Antiepileptic Medications with Outcomes after Allogeneic Hematopoietic Cell Transplantation with Busulfan/Cyclophosphamide Conditioning.

Authors:  Jeannine S McCune; Tao Wang; Khalid Bo-Subait; Mahmoud Aljurf; Amer Beitinjaneh; Joseph Bubalo; Jean-Yves Cahn; Jan Cerny; Saurabh Chhabra; Aaron Cumpston; L Lee Dupuis; Hillard M Lazarus; David I Marks; Richard T Maziarz; Maxim Norkin; Tim Prestidge; Shin Mineishi; Maxwell M Krem; Marcelo Pasquini; Paul J Martin
Journal:  Biol Blood Marrow Transplant       Date:  2019-03-11       Impact factor: 5.742

5.  Minimal incidence of neurotoxicity without prophylaxis during busulfan-based conditioning regimen in patients undergoing stem cell transplantation.

Authors:  Eucario Leon-Rodriguez; Monica M Rivera-Franco
Journal:  Int J Hematol       Date:  2016-10-08       Impact factor: 2.490

6.  In vivo distribution of [11C]-busulfan in cynomolgus monkey and in the brain of a human patient.

Authors:  M Hassan; G Oberg; K Ericson; H Ehrsson; L Eriksson; M Ingvar; S Stone-Elander; J O Thorell; B Smedmyr; N Warne
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

7.  Disposition of total and unbound etoposide following high-dose therapy.

Authors:  T L Schwinghammer; R A Fleming; C S Rosenfeld; D Przepiorka; R K Shadduck; E J Bloom; C F Stewart
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

8.  Influence of prophylactic anticonvulsant therapy on high-dose busulphan kinetics.

Authors:  M Hassan; G Oberg; M Björkholm; I Wallin; M Lindgren
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

Review 9.  Busulfan in hematopoietic stem cell transplantation.

Authors:  Stefan O Ciurea; Borje S Andersson
Journal:  Biol Blood Marrow Transplant       Date:  2009-02-12       Impact factor: 5.742

10.  Pharmacokinetics of high-dose busulfan in children.

Authors:  G Vassal; A Gouyette; O Hartmann; J L Pico; J Lemerle
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.